---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-084088"
form_type: "8-K/A"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2026-07-16T12:01:18+00:00"
generated_at: "2026-07-16T12:05:14.651683+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Edgewise closes $1.55B sale of sevasemten to Servier; pivots to cardiovascular pipeline

## Summary
- Received $1.55B upfront cash; eligible for up to $1.1B in regulatory/commercial milestones.
- Pro forma cash at March 31, 2026: $1.53B (up from $33.2M historical).
- Pro forma net income for FY2025: $1.1355B (vs. historical net loss of $167.8M).
- Company now focused on cardiovascular assets EDG-7500, EDG-15400, and EDG-003.
- Transition Services Agreement with Servier: at least 18 months; $17.9M deferred liability.

## SEC filing metadata
- accession: 0001104659-26-084088
- form_type: 8-K/A
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2026-07-16T12:01:18+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465926084088/0001104659-26-084088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465926084088/tm2620181d2_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-084088
- JSON: https://secwatch.observer/filing/0001104659-26-084088.json
- Plain text: https://secwatch.observer/filing/0001104659-26-084088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.